Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNLG NHL VIII: CID vs CD and Interferon Maintenance in Low Grade NHL
NCT00003639Phase 3Unknown
- Sponsor
- Scotland and Newcastle Lymphoma Group
- Start
- Nov 1993
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of idarubicin and interferon alfa in non-Hodgkin lymphoma (NHL) (5 arms), sponsored by Scotland and Newcastle Lymphoma Group. Primary endpoints: Remission Induction Rate at 18 weeks and Toxicity at 18 weeks. Status: unknown.
02
Drugs
idarubicininterferon alfa
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003639.